21st Century Therapeutics, Inc.

Detroit, MI 48202

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $2.74MM
First Award Date 09/26/05
Most Recent Award Date 08/15/15

Key Personnel

Last Name Name Awards Contact
Betts Russell Lloyd Betts 1
Shaw Jiajiu Shaw 6
CHEN BEN D. CHEN 2

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/15/15 - 03/15/16

? DESCRIPTION (provided by applicant): Methicillin-resistant staphylococcus aureus (MRSA) is a serious pathogen that can cause patient mortality and extend hospital stays, resulting in higher health care costs. Currently, over 50% of staph cases around the world are caused by MRSA. In recent years, MRSA has evolved into several resistant str...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/15/15 - 03/15/16

DESCRIPTION (provided by applicant): Methicillin-resistant staphylococcus aureus (MRSA) is a serious pathogen that can cause patient mortality and extend hospital stays, resulting in higher health care costs. Currently, over 50% of staph cases around the world are caused by MRSA. In recent years, MRSA has evolved into several resistant strains ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 06/01/15 - 05/31/16

DESCRIPTION (provided by applicant): Janus kinase 3 (JAK3) is an intracellular kinase involved in cytokine and antibody receptor signaling; it is frequently over-activated during the course of inflammatory autoimmune diseases. Therefore, suitable JAK3 inhibitors that modulate the overexpression of JAK3 may be potential agents for treating autoim...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 06/05/14 - 05/31/15

DESCRIPTION (provided by applicant): Janus kinase 3 (JAK3) is an intracellular kinase involved in cytokine and antibody receptor signaling;it is frequently over-activated during the course of inflammatory autoimmune diseases. Therefore, suitable JAK3 inhibitors that modulate the overexpression of JAK3 may be potential agents for treating autoimm...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 05/01/13 - 04/30/14

DESCRIPTION (provided by applicant): Although oxaliplatin is a third-generation platinum drug, it has become the most prescribed amongst all platinum drugs overtaking its predecessors, cisplatin and carboplatin. To date, oxaliplatin has become an integral part of various chemotherapy protocols, especially in advanced colorectal cancer. For color...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/01/12 - 07/31/13

DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprotective agent which reduces the side effects of cisplatin without affecting its efficacy woul...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/23/11 - 07/31/12

DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprotective agent which reduces the side effects of cisplatin without affecting its efficacy woul...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/01/09 - 01/31/11

DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprotective agent which reduces the side effects of cisplatin without affecting it efficacy would...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/26/05 - 09/30/07

DESCRIPTION (provided by applicant): Metastatic solid tumors (colon, breast, ovary, lung and prostate) comprise 50% of all human cancers and account for half of all the mortality in the population of the United States. 21st Century Therapeutics, Inc (21CTI) is an anticancer drug discovery and development company whose focus is to discover, devel...